QuellTX
Dafne Franz Demane has a diverse work experience in various scientific research roles. Dafne currently works as a Scientist II at Quell Therapeutics since December 2022. Prior to this, they were a Postdoctoral Research Associate at UCL Cancer Institute from October 2018, with no mention of an end date. Dafne also worked as a PhD student at UCL Cancer Institute from September 2014 to September 2018. Dafne's previous experience includes working as a Senior Scientist at Advent Bioservices from March 2021 to December 2022. Dafne started their career as a Research Assistant at Fundación Ciencia & Vida from October 2011, with an end date not specified, and had previously served as an Undergraduate Student Researcher at the same organization from March 2010 to January 2012.
Dafne Franz Demane has a strong educational background in the field of molecular biotechnology and cancer immunotherapy. They completed their Doctor of Philosophy (PhD) in Cancer Immunotherapy at the UCL Cancer Institute from 2014 to 2018. Prior to that, Dafne earned a Bachelor of Science (BS) degree in Molecular Biotechnology Engineering from Universidad de Chile, where they studied from 2006 to 2011. Additionally, Dafne obtained an Academic Bachelor degree with a major in Exact and Natural Sciences from the same institution in 2006.
In terms of additional certifications, Dafne has completed several courses to enhance their professional skills. They obtained certifications in "Negotiating Your Leadership Success" and "Rock Your LinkedIn Profile" from LinkedIn in June 2020. In June 2019, they completed the "SPERO Discover: Entrepreneurial skills for UCL-wide PhDs & Doctoral students" workshop offered by UCL Innovation & Enterprise. They also completed a workshop on "Colony Management: Principles and Practices" at The Jackson Laboratory in April 2012.
This person is not in the org chart
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.